 Aeterna Zentaris Inc NASDAQ: AEZS has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency CGHD. The investigational new drug application multicenter, open-label trial will investigate the efficacy and safety of a single oral dose of 1.0 mgkg macimorelin acetate as a growth hormone stimulation test GHST in pediatric patients with suspected GHD. 